Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem, Inc. (Verastem Oncology, Nasdaq: VSTM) is a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, and its news flow reflects both commercial progress and active clinical development. Company press releases emphasize the U.S. launch and ongoing adoption of AVMAPKI FAKZYNJA CO-PACK, an FDA-approved combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer, as well as updates on confirmatory and expansion trials built around this therapy.
Investors following VSTM news can expect regular updates on clinical trial milestones, including the Phase 3 RAMP 301 confirmatory study in recurrent LGSOC, the RAMP 205 trial in first-line metastatic pancreatic cancer, and the now-discontinued RAMP 203 study in KRAS G12C-mutated NSCLC. Verastem also issues detailed communications on early-stage programs such as VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, covering dose-escalation progress, preliminary safety and efficacy signals, and combination strategies with agents like cetuximab.
Beyond clinical data, Verastem’s news includes capital markets events such as public offerings of common stock and pre-funded warrants, as well as corporate updates on leadership changes and participation in healthcare and investor conferences. These announcements provide context on how the company is funding and prioritizing its RAS/MAPK-focused portfolio.
Stock Titan’s VSTM news page aggregates these company-issued releases and related coverage into a single, organized feed. Readers can use this page to track developments in AVMAPKI FAKZYNJA CO-PACK commercialization, monitor progress of key trials like RAMP 301 and VS-7375-101, and follow Verastem’s financing and strategic communications over time.
Verastem Oncology (Nasdaq: VSTM) has announced its management team's upcoming participation in two major investor conferences. The company will attend the 2024 Truist Securities BioPharma Symposium on November 7 and participate in a fireside chat at the 2024 Guggenheim Healthcare Innovation Conference on November 13 at 9:00 am EDT.
The fireside chat will be accessible via live webcast in the Events & Presentations section of Verastem's website, with a replay available for approximately 90 days post-presentation.
Verastem Oncology presented updated data from the Phase 2 RAMP 201 trial evaluating avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2024 Annual Meeting. Key findings include:
- 31% overall response rate (44% in KRAS mutant, 17% in KRAS wild-type)
- Median progression-free survival of 12.9 months (22 months in KRAS mutant)
- Disease control rate at 6+ months: 61% overall (70% KRAS mutant, 50% KRAS wild-type)
- Generally well-tolerated with 10% discontinuation rate due to adverse events
Verastem plans to complete NDA submission in October 2024 for adult patients with recurrent KRAS mutant LGSOC, seeking Accelerated Approval and Priority Review from the FDA. The company aims to bring the first FDA-approved treatment for this specific indication to market in 2025.
Verastem Oncology (Nasdaq: VSTM) announced details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 clinical trial at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Dublin, Ireland. The presentation, scheduled for October 17, 2024, at 11:42 AM ET, will include updated safety and efficacy data on the combination of avutometinib and defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC).
The company will host an investor conference call and webcast on the same day at 4:30 PM EDT to review the trial data. The presentation will cover overall response rate, progression-free survival, and duration of response. Professor Susana N. Banerjee, the global lead investigator, will present the findings.
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on developing new cancer medicines, has announced the grant of stock options to nine new employees. These options allow the purchase of 109,000 shares of common stock at an exercise price of $2.82 per share, which was the closing price on October 1, 2024.
The grants were made under the Nasdaq inducement grant exception, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, with 25% vesting on the one-year anniversary of each employee's hire date, and the remaining shares vesting quarterly over the following three years in equal amounts. Vesting is contingent on continued employment or service provision to Verastem Oncology.
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on developing new cancer medicines, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management team will engage in a fireside chat on Wednesday, September 18 at 3:40 pm EDT.
Interested parties can access a live webcast of the discussion through the 'Events & Presentations' section of Verastem's website. For those unable to attend live, a replay of the webcast will be available on the company's website for approximately 90 days following the presentation.
Verastem Oncology (VSTM) announced the acceptance of a late-breaking abstract for oral presentation at the International Gynecologic Cancer Society (IGCS) Annual Meeting in October 2024. The presentation will feature mature data from the Phase 2 RAMP 201 clinical trial, evaluating the combination of avutometinib (RAF/MEK clamp) and defactinib (FAK inhibitor) in patients with low-grade serous ovarian cancer (LGSOC).
The presentation will include updated safety and efficacy data, including overall response rate, progression-free survival, and duration of response. Verastem Oncology's CEO, Dan Paterson, highlighted that the robust interim data from RAMP 201 enabled the initiation of a rolling NDA submission to the FDA. The company remains on track to complete its NDA submission in Q4 2024.
Verastem Oncology (NASDAQ: VSTM) and STAAR Ovarian Cancer Foundation have established the first Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024. LGSOC is a rare ovarian cancer often affecting younger women, with no FDA-approved treatments. The initiative aims to educate about LGSOC symptoms, provide resources, and advocate for more research.
Key points:
- Approximately 80% of LGSOC patients experience cancer recurrence
- 99% of surveyed patients had no awareness of LGSOC prior to diagnosis
- 60% felt their healthcare provider was not very knowledgeable about LGSOC
- Verastem is conducting clinical trials for an investigational treatment combination for LGSOC
- The company has initiated a rolling new drug application with the FDA for a potential LGSOC-specific treatment
Verastem Oncology (Nasdaq: VSTM) reported Q2 2024 financial results and business updates. Key highlights include:
1. Initiated rolling NDA submission for avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer.
2. Presented positive initial interim results from RAMP 205 trial in first-line metastatic pancreatic cancer at ASCO 2024.
3. Cash position of $83.4 million as of June 30, 2024; pro forma $144.5 million including recent financing and milestone payment.
4. Q2 2024 revenue of $10 million from COPIKTRA sales milestone.
5. Net loss of $8.3 million, or $0.31 per share for Q2 2024.
6. Expects to complete NDA submission in H2 2024 and potential U.S. commercial launch in 2025.
Verastem Oncology (Nasdaq: VSTM) has received FDA Orphan Drug Designation for avutometinib and defactinib in treating pancreatic cancer. This combination therapy, along with standard chemotherapy, showed promising results in the ongoing RAMP 205 trial for first-line metastatic pancreatic cancer. Initial interim data presented at ASCO 2024 revealed an 83% confirmed partial response rate in the dose level 1 cohort. The company plans to report updated data from the trial in Q1 2025. The Orphan Drug Designation recognizes the unmet need in pancreatic cancer treatment and offers benefits such as tax credits and potential market exclusivity.
Verastem Oncology (Nasdaq: VSTM) has announced the pricing of a $55.0 million public offering of common stock, warrants, and pre-funded warrants. The offering includes 13,333,334 shares of common stock and warrants at $3.00 per share, and 5,000,000 pre-funded warrants with accompanying warrants at $2.999 each. The warrants have an exercise price of $3.50 per share and will expire in 18 months.
The company plans to use the proceeds for the potential launch of avutometinib and defactinib in LGSOC, continued clinical research and development, working capital, and other corporate purposes. Guggenheim Securities and Cantor are acting as joint book-running managers for the offering, which is expected to close on July 25, 2024.